Immune Modulation in Hematologic Malignancies

Seminars in Oncology

Volumn 42, Issue 4, 2015, Pages 617-625

  Dhodapkar, Madhav V ^a,b,c   Dhodapkar, Kavita M ^b,d  

^a Departments of Internal Medicine (Hematology)   (United States)

^b Pediatrics (Hematology Oncology)   (United States)

^c YALE UNIVERSITY   (United States)

^d YALE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; LENALIDOMIDE; MONOCLONAL ANTIBODY; POMALIDOMIDE; RITUXIMAB; THALIDOMIDE; VACCINE;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CELL FUNCTION; CELL THERAPY; CELLULAR IMMUNITY; GENE EXPRESSION; HEMATOLOGIC MALIGNANCY; HODGKIN DISEASE; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOMODULATION; IMMUNOTHERAPY; MYELOID DERIVED SUPPRESSOR CELL; NONHODGKIN LYMPHOMA; ONCOLYTIC VIROTHERAPY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REGULATORY T LYMPHOCYTE; SUPPRESSOR CELL; T LYMPHOCYTE; TUMOR GROWTH; TUMOR MICROENVIRONMENT; ADOPTIVE IMMUNOTHERAPY; HEMATOLOGIC NEOPLASMS; IMMUNOLOGY; PROCEDURES;

ANTIBODIES, MONOCLONAL; HEMATOLOGIC NEOPLASMS; HUMANS; IMMUNE SYSTEM; IMMUNOMODULATION; IMMUNOTHERAPY, ADOPTIVE;

EID: 84940387185     PISSN: 00937754     EISSN: 15328708     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2015.05.009     Document Type: Review

References (87)

1. S.G. Tangye, C.S. Ma, R. Brink, and E.K. Deenick good, bad and ugly - TFH cells in human health and disease Nat Rev Immunol 13 6 2013 412 426
2. A. Kukreja, A. Hutchinson, K. Dhodapkar, and et al. Enhancement of clonogenicity of human multiple myeloma by dendritic cells J Exp Med 203 8 2006 1859 1865
3. K. Tokoyoda, A.E. Hauser, T. Nakayama, and A. Radbruch Organization of immunological memory by bone marrow stroma Nat Rev Immunol 10 3 2010 193 200
4. M.V. Dhodapkar, J. Krasovsky, K. Osman, and M.D. Geller Vigorous premalignancy specific effector T cell response in bone marrow of patients with preneoplastic gammopathy J Exp Med 198 2003 1753 1757
5. R. Spisek, A. Kukreja, L.C. Chen, and et al. Frequent and specific immunity to embryonal stem cell-associated antigen SOX2 in patients with monoclonal gammopathy J Exp Med 204 4 2007 831 840
6. M.V. Dhodapkar, J. Krasovsky, and K. Olson T cells from tumor microenvironment of patients with progressive myeloma can generate strong, tumor-specific cytolytic responses to autologous, tumor-loaded dendritic cells Proc Natl Acad Sci U S A 99 20 2002 13009 13013
7. K. Noonan, W. Matsui, P. Serafini, and et al. Activated marrow-infiltrating lymphocytes effectively target plasma cells and ir clonogenic precursors Cancer Res 65 5 2005 2026 2034
8. D.M. Pardoll blockade of immune checkpoints in cancer immunorapy Nat Rev Cancer 12 4 2012 252 264
9. D. Chauhan, A.V. Singh, M. Brahmandam, and et al. Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: A rapeutic target Cancer Cell 16 4 2009 309 323
10. S. Koduru, E. Wong, T. Strowig, and et al. Dendritic cell-mediated activation-induced cytidine deaminase (AID)-dependent induction of genomic instability in human myeloma Blood 119 10 2012 2302 2309
11. S.S. Dave, G. Wright, B. Tan, and et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells N Engl J Med 351 21 2004 2159 2169
12. P. Greaves, A. Clear, A. Owen, and et al. Defining characteristics of classical Hodgkin lymphoma microenvironment T-helper cells Blood 122 16 2013 2856 2863
13. C. Steidl, T. Lee, S.P. Shah, and et al. Tumor-associated macrophages and survival in classic Hodgkin's lymphoma N Engl J Med 362 10 2010 875 885
14. C. Steidl, S.P. Shah, B.W. Woolcock, and et al. MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers Nature 471 7338 2011 377 381
15. M.R. Green, S. Monti, S.J. Rodig, and et al. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and furr induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma Blood 116 17 2010 3268 3277
16. S.A. Riemersma, E.S. Jordanova, R.F. Schop, and et al. Extensive genetic alterations of HLA region, including homozygous deletions of HLA class II genes in B-cell lymphomas arising in immune-privileged sites Blood 96 10 2000 3569 3577
17. N.J. Bahlis, A.M. King, D. Kolonias, and et al. CD28-mediated regulation of multiple myeloma cell proliferation and survival Blood 109 11 2007 5002 5010
18. E. Baecklund, K.E. Smedby, L.A. Sutton, J. Askling, and R. Rosenquist Lymphoma development in patients with autoimmune and inflammatory disorders - what are driving forces? Semin Cancer Biol 24 2014 61 70
19. K.P. MacDonald, W.D. Shlomchik, and P. Reddy Biology of graft-versus-host responses: recent insights Biol Blood Marrow Transplant 19 1 Suppl 2013 S10 S14
20. P.A. Haslett, L.G. Corral, M. Albert, and G. Kaplan Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in CD8+subset J Exp Med 187 11 1998 1885 1892
21. A. Palumbo, and K. Anderson Multiple myeloma N Engl J Med 364 11 2010 1046 1060
22. F.E. Davies, N. Raje, T. Hideshima, and et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma Blood 98 1 2001 210 216
23. J. Richter, N. Neparidze, L. Zhang, and et al. Clinical regressions and broad immune activation following combination rapy targeting human NKT cells in myeloma Blood 121 3 2013 423 430
24. J.D. Licht, J. Shortt, and R. Johnstone From anecdote to targeted rapy: Curious case of thalidomide in multiple myeloma Cancer Cell 25 1 2014 9 11
25. A.K. Gandhi, J. Kang, C.G. Havens, and et al. Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of E3 ubiquitin ligase complex CRL4(CRBN.) Br J Haematol 164 6 2014 811 821
26. J. Kronke, N.D. Udeshi, A. Narla, and et al. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells Science 343 6168 2014 301 305
27. D.H. Chang, N. Liu, V. Klimek, and et al. Enhancement of ligand dependent activation of human natural killer T cells by lenalidomide: rapeutic implications Blood 108 2 2006 618 621
28. Y.T. Tai, X.F. Li, L. Catley, and et al. Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: Clinical implications Cancer Res 65 24 2005 11712 11720
29. U. Vitolo, A. Chiappella, S. Franceschetti, and et al. Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of REAL07 open-label, multicentre, phase 2 trial Lancet Oncol 15 7 2014 730 737
30. L.M. Weiner, M.V. Dhodapkar, and S. Ferrone Monoclonal antibodies for cancer immunorapy Lancet 373 9668 2009 1033 1040
31. R.A. Clynes, T.L. Towers, L.G. Presta, and J.V. Ravetch Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets Nat Med 6 4 2000 443 446
32. W.G. Wierda, T.J. Kipps, J. Mayer, and et al. Ofatumumab as single-agent CD20 immunorapy in fludarabine-refractory chronic lymphocytic leukemia J Clin Oncol 28 10 2010 1749 1755
33. V. Goede, K. Fischer, R. Busch, and et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions N Engl J Med 370 12 2014 1101-0
34. S.A. Beers, C.H. Chan, R.R. French, M.S. Cragg, and M.J. Glennie CD20 as a target for rapeutic type I and II monoclonal antibodies Semin Hematol 47 2 2010 107 114
35. S. Lonial, R. Vij, J.L. Harousseau, and et al. Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma J Clin Oncol 30 16 2012 1953 1959
36. M. de Weers, Y.T. Tai, M.S. van der Veer, and et al. Daratumumab, a novel rapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and or hematological tumors J Immunol 186 3 2011 1840 1848
37. A. Younes, N.L. Bartlett, J.P. Leonard, and et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas N Engl J Med 363 19 2010 1812 1821
38. M.S. Topp, N. Gokbuget, G. Zugmaier, and et al. Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL Blood 120 26 2012 5185 5187
39. S.J. Schuster, S.S. Neelapu, B.L. Gause, and et al. Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma J Clin Oncol 29 20 2011 2787 2794
40. A. Freedman, S.S. Neelapu, C. Nichols, and et al. Placebo-controlled phase III trial of patient-specific immunorapy with mitumprotimut-T and granulocyte-macrophage colony-stimulating factor after rituximab in patients with follicular lymphoma J Clin Oncol 27 18 2009 3036 3043
41. V.F. Van Tendeloo, A. Van de Velde, A. Van Driessche, and et al. Induction of complete and molecular remissions in acute myeloid leukemia by Wilms' tumor 1 antigen-targeted dendritic cell vaccination Proc Natl Acad Sci U S A 107 31 2010 13824 13829
42. U. Keilholz, A. Letsch, A. Busse, and et al. A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS Blood 113 26 2009 6541 6548
43. P.F. Robbins, Y.C. Lu, M. El-Gamil, and et al. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells Nat Med 19 6 2013 747 752
44. S. Anguille, E.L. Smits, E. Lion, V.F. van Tendeloo, and Z.N. Berneman Clinical use of dendritic cells for cancer rapy Lancet Oncol 15 7 2014 e257 e267
45. M.V. Dhodapkar, M. Sznol, B. Zhao, and et al. Induction of antigen-specific immunity with a vaccine targeting NY-ESO-1 to dendritic cell receptor DEC-205 Sci Transl Med 6 232 2014 232ra251 2014
46. Y. Lin, L. Zhang, A.X. Cai, and et al. Effective posttransplant antitumor immunity is associated with TLR-stimulating nucleic acid-immunoglobulin complexes in humans J Clin Invest 121 4 2011 1574 1584
47. M. Obeid, A. Tesniere, F. Ghiringhelli, and et al. Calreticulin exposure dictates immunogenicity of cancer cell death Nat Med 13 1 2007 54 61
48. R. Spisek, A. Charalambous, A. Mazumder, and et al. Bortezomib enhances dendritic cell (DC) mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: rapeutic implications Blood 109 2007 4839 4845
49. L. Zitvogel, O. Kepp, and G. Kroemer Decoding cell death signals in inflammation and immunity Cell 140 6 2010 798 804
50. A.C. West, M.J. Smyth, and R.W. Johnstone anticancer effects of HDAC inhibitors require immune system Oncoimmunology 3 1 2014 e27414
51. J.A. Dubovsky, K.A. Beckwith, G. Natarajan, and et al. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes Blood 122 15 2013 2539 2549
52. S.J. Russell, M.J. Federspiel, K.W. Peng, and et al. Remission of disseminated cancer after systemic oncolytic virorapy Mayo Clin Proc 89 7 2014 926 933
53. M.V. Maus, S.A. Grupp, D.L. Porter, and C.H. June Antibody-modified T cells: CARs take front seat for hematologic malignancies Blood 123 17 2014 2625 2635
54. + T cells J Exp Med 202 7 2005 907 912
55. G.P. Linette, E.A. Stadtmauer, M.V. Maus, and et al. Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma Blood 122 6 2013 863 871
56. D.L. Porter, B.L. Levine, M. Kalos, A. Bagg, and C.H. June Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia N Engl J Med 365 8 2011 725 733
57. S.A. Grupp, M. Kalos, D. Barrett, and et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia N Engl J Med 368 16 2013 1509 1518
58. R.J. Brentjens, M.L. Davila, I. Riviere, and et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemorapy-refractory acute lymphoblastic leukemia Sci Transl Med 5 177 2013 177ra138 2013
59. S.L. Maude, N. Frey, P.A. Shaw, and et al. Chimeric antigen receptor T cells for sustained remissions in leukemia N Engl J Med 371 16 2014 1507 1517
60. D.W. Lee, J.N. Kochenderfer, M. Stetler-Stevenson, and et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: A phase 1 dose-escalation trial Lancet 385 9967 2015 517 528
61. M.L. Davila, I. Riviere, X. Wang, and et al. Efficacy and toxicity management of 19-28z CAR T cell rapy in B cell acute lymphoblastic leukemia Sci Transl Med 6 224 2014 224ra225 2014
62. M.V. Maus, and C.H. June CARTs on road for myeloma Clin Cancer Res 20 15 2014 3899 3901
63. D. Sommermeyer, H. Conrad, H. Kronig, and et al. NY-ESO-1 antigen-reactive T cell receptors exhibit diverse rapeutic capability Int J Cancer 132 6 2013 1360 1367
64. L. Ruggeri, M. Capanni, E. Urbani, and et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants Science 295 5562 2002 2097 2100
65. J.M. Venstrom, G. Pittari, T.A. Gooley, and et al. HLA-C-dependent prevention of leukemia relapse by donor activating KIR2DS1 N Engl J Med 367 9 2012 805 816
66. V. Bachanova, S. Cooley, T.E. Defor, and et al. Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphria toxin fusion protein Blood 123 25 2014 3855 3863
67. V. Bachanova, and J.S. Miller NK cells in rapy of cancer Crit Rev Oncog 19 1-2 2014 133 141
68. D.M. Benson Jr., C.C. Hofmeister, S. Padmanabhan, and et al. A phase 1 trial of anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma Blood 120 22 2012 4324 4333
69. N. Vey, J.H. Bourhis, N. Boissel, and et al. A phase 1 trial of anti-inhibitory KIR mAb IPH2101 for AML in complete remission Blood 120 22 2012 4317 4323
70. M.V. Dhodapkar, M.D. Geller, D.H. Chang, and et al. A reversible defect in natural killer T cell function characterizes progression of premalignant to malignant multiple myeloma J Exp Med 197 12 2003 1667 1676
71. D.H. Chang, K. Osman, J. Connolly, and et al. Sustained expansion of NKT cells and antigen-specific T cells after injection of {alpha}-galactosyl-ceramide loaded mature dendritic cells in cancer patients J Exp Med 201 9 2005 1503 1517
72. D.B. Page, M.A. Postow, M.K. Callahan, J.P. Allison, and J.D. Wolchok Immune modulation in cancer with antibodies Annu Rev Med 65 2014 185 202
73. L.J. Bryan, and L.I. Gordon Blocking tumor escape in hematologic malignancies: Anti-PD-1 strategy Blood Rev 29 1 2015 25 32
74. J. Liu, A. Hamrouni, D. Wolowiec, and et al. Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-{gamma} and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway Blood 110 1 2007 296 304
75. S.M. Ansell, S.A. Hurvitz, P.A. Koenig, and et al. Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphoma Clin Cancer Res 15 20 2009 6446 6453
76. A. Bashey, B. Medina, S. Corringham, and et al. CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation Blood 113 7 2009 1581 1588
77. P. Armand, A. Nagler, E.A. Weller, and et al. Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial J Clin Oncol 31 33 2013 4199 4206
78. J.R. Westin, F. Chu, M. Zhang, and et al. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: A single group, open-label, phase 2 trial Lancet Oncol 15 1 2014 69 77
79. A.M. Lesokhin, S.M. Ansel, P. Armand, and et al. Preliminary results of a phase I study of nivolumab (BMS-936558) in patients with relapsed or refractory lymphoid malignancies. (meeting abstract) Blood 2014 291
80. P. Armand, S.M. Ansell, A.M. Lesokhin, and et al. Nivolumab in patients with relapsed or refractory hodgkin lymphoma- preliminary safety, efficacy and biomarker results of a phase I study. (meeting abstract) Blood 2014 289
81. C. Moskowitz, V. Ribrag, J.M. Michot, and et al. PD-1 blockade with monoclonal antibody Pembromizumab (MK-3475) in patients wth classical hodgkins lymphoma after brentuximab vedotin failure: Preliminary results from a phase Ib study (KEYNOTE-013) Blood 2014 Meeting abstract:290
82. S.M. Ansell, A.M. Lesokhin, I. Borrello, and et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma N Engl J Med 372 4 2015 311 319
83. J.D. Wolchok, H. Kluger, M.K. Callahan, and et al. Nivolumab plus ipilimumab in advanced melanoma N Engl J Med 369 2 2013 122 133
84. R. Das, R. Verma, M. Sznol, and et al. Combination rapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo J Immunol 2014
85. J. Dubrot, F. Milheiro, C. Alfaro, and et al. Treatment with anti-CD137 mAbs causes intense accumulations of liver T cells without selective antitumor immunorapeutic effects in this organ Cancer Immunol Immunor 59 8 2010 1223 1233
86. R. Houot, H. Kohrt, and R. Levy Boosting antibody-dependant cellular cytotoxicity against tumor cells with a CD137 stimulatory antibody Oncoimmunology 1 6 2012 957 958
87. H.E. Kohrt, R. Houot, M.J. Goldstein, and et al. CD137 stimulation enhances antilymphoma activity of anti-CD20 antibodies Blood 117 8 2011 2423 2432